Zevra Therapeutics, Inc. (ZVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.40-1.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — MIPLYFFA net revenue growth to at least $106.5 million: Q2 FY26 rev $39.7M vs $106.5M target.
Zevra grows MIPLYFFA net revenue to $106.5 million in 2025. The company beat earnings in recent quarters. It repaid all credit obligations in 2026. The stock is cheap versus peers and has room to rise.
Zevra's profit per share is negative in guidance. Revenue growth may slow after 2025. The company has fragile quality and high risk. Analyst estimates have recently fallen.
The price is about 4% below our fair value near $15. Analysts expect 31% revenue growth. Our fair value is 48% below the Street median, showing caution.
Breaks if: new credit obligations arise
Breaks if: EPS falls below $1.0 in 2026
Breaks if: net revenue falls below $100 million in 2025
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
ZVRA represents a speculative growth investment. The company is currently loss-making but has shown strong recent financial performance, particularly in its MIPLYFFA net revenue growth.
The market appears to price ZVRA as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential for continued revenue growth and sector momentum.
Management's focus on growth in MIPLYFFA revenue and advancing clinical trials indicates a positive trajectory for fundamentals. Recent financial results have been strong, but the company operates in a high-miss-rate industry, which introduces some risk.
The thesis hinges on the company's ability to maintain its growth trajectory and manage risks effectively. Key factors include guidance updates and the performance of sector bellwethers, which could influence ZVRA's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue to grow net revenue from MIPLYFFA, the approved therapy for Niemann-Pick disease type C, through U.S. commercial execution and geographic expansion.
Stated as a priority in 3 of last 3 quarters. MIPLYFFA net revenue grew from $24.6 million in 2026-Q1 to $30.2 million in 2026-Q2, contributing to FY 2025 net revenue of $87.4 million. Management consistently emphasizes MIPLYFFA growth, and the revenue trajectory is delivering on this priority.
“Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment option for NPC”
“Continued performance for MIPLYFFA, underscoring its role in addressing the needs of patients with NPC”
“Growth in MIPLYFFA® net revenue to $87.4 million in FY 2025”
Overall, ZVRA's fundamentals and management execution support a positive outlook over the next 1 to 3 years. Not investment advice.